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Abstract
The rate of 13C-label incorporation into both aspartyl (NAA C3)
and acetyl (NAA C6) groups of N-acetyl aspartate (NAA) was
simultaneously measured in the rat brain in vivo for up to 19 h
of [1-13C]glucose infusion (n ¼ 8). Label incorporation was
detected in NAA C6 approximately 1.5 h earlier than in NAA
C3 because of the delayed labeling of the precursor of NAA
C3, aspartate, compared to that of NAA C6, glucose. The time
courses of NAA were fitted using a mathematical model
assuming synthesis of NAA in one kinetic compartment with
the respective precursor pools of aspartate and acetyl coen-
zyme A (acetyl-CoA). The turnover rates of NAA C6 and C3
were 0.7 ± 0.1 and 0.6 ± 0.1 lmol/(g h) with the time con-
stants 14 ± 2 and 13 ± 2 h, respectively, with an estimated
pool size of 8 lmol/g. The results suggest that complete label
turnover of NAA from glucose occurs in approximately 70 h.
Several hours after starting the glucose infusion, label incor-
poration into glutathione (GSH) was also detected. The turn-
over rate of GSH was 0.06 ± 0.02 lmol/(g h) with a time
constant of 13 ± 2 h. The estimated pool size of GSH was
0.8 lmol/g, comparable to the cortical glutathione concentra-
tion. We conclude that NAA and GSH are completely turned
over and that the metabolism is extremely slow (< 0.05% of
the glucose metabolic rate).
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The measurement of a neurochemical turnover using 13C as a
‘tracer’ has provided an opportunity to explore metabolic
ﬂuxes and an important parameter to study brain energy
metabolism (Cerdan et al. 1990; Bachelard and Badar-Goffer
1993; Gruetter 2002). Using in vivo 13C NMR, the metabolic
rate of neurochemicals can be assessed by measuring the rate
of label incorporation from the 13C-labeled precursor into
metabolites, including amino acids. When considering
metabolic steady state ( i.e. metabolite concentrations and
ﬂux rates are assumed constant in time), a rapid rise in
isotopic enrichment of the precursor results in labeling of
metabolites, which is in general slower than that of the
precursor. The labeling turnover time is related to the label
half-life, the pool size and the turnover (or metabolic) rate
assuming concentration changes of metabolites are small at
steady state (for details see Choi and Gruetter 2003; Gruetter
2004). Therefore, label incorporation into various neuro-
chemicals occurs on a distinctively different time scale. For
example, label incorporation into glucose, glutamate/gluta-
mine and glycogen occurs with a label half-life, T1/2 (T1/2 is
typically deﬁned as the time it takes to replace half the 12C
with 13C and vice versa, following a step change in precursor
enrichment), on the order of 10 min, 1–2 h and > 10 h,
respectively (Hyder et al. 1996; Choi and Gruetter 2000,
2003). Although the label turnover of major amino acids
from [13C]glucose, such as glutamate and glutamine, has
been well studied and reported to be relatively fast (Rothman
et al. 1999; Gruetter 2002), that of N-acetyl aspartate (NAA)
and glutathione (GSH) has been rarely measured in vivo and
is considered to be very slow or maybe inert (Clarke et al.
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1975; Kunnecke et al. 1993; Chang et al. 1997; Gruetter
et al. 1998b; Tyson and Sutherland 1998; Moreno et al.
2001). Therefore, we sought to measure the turnover rate of
two slow metabolites, NAA and GSH.
NAA is the most abundant amino acid in the adult brain,
reaching concentrations on the order of 10 lmol/g, and is of
increasing importance in medical diagnostics. NAA is
localized to neurons (Nadler and Cooper 1972) and under-
goes dramatic increases during brain development in all
regions of the rat brain (Tallan 1957; Tkac et al. 2003),
suggesting important, as of yet unknown roles in brain
function (for reviews, see Clark 1998; Baslow 2003). Even
though its precise function in the central nervous system
remains elusive, NAA has been recognized as a putative
neuronal marker, possibly reﬂecting neuronal cell volume
(Meyerhoff et al. 1993). However, this role assumes that
there is little or no active NAA metabolism that might alter
its concentration. The biosynthesis of NAA occurs in the
neuro-axonal compartment from its precursors, aspartate and
acetyl coenzyme A (acetyl-CoA), through the action of the
enzyme, L-aspartate-N-acetyltransferase, or from N-acetyl
aspartyl glutamate (NAAG) by N-acetylated a-linked amino
dipeptidase (Tyson and Sutherland 1998). NAA is then
transported from the mitochondrion to the cytoplasm, and
metabolized by N-acetylaspartate amidohydrolase (or aspar-
toacylase) to yield aspartate and acetate, and releasing amino
nitrogen and carbon in the cytosol. Many functions have
been proposed for NAA, including osmoregulation (Taylor
et al. 1995; Baslow 2000) or as a precursor of acetate. It may
also be a breakdown product of the neurotransmitter NAAG
(Blakely and Coyle 1988). Another proposed role of NAA
may be a facet of a storage form of aspartate, acetyl-CoA,
and acetyl groups for myelin synthesis (D’Adamo et al.
1968). Lastly, NAA has also been proposed to serve as a
mitochondrial shuttle of acetyl-CoA used for fatty acid
synthesis (D’Adamo and Yatsu 1966).
It is accepted that NAA metabolism is very slow
compared to the cerebral metabolic rates of glucose and
oxygen (Tyson and Sutherland 1998). Nonetheless, a
quantitative assessment of NAA metabolism may provide
important insight into the neuronal and mitochondrial
integrity of the brain in health and various neurological
disorders. The endogenous NAA pool was thought to be
virtually metabolically inert because of its slow label
incorporation after the administration of 14C- or 13C-labeled
precursors (Jacobson 1959; Margolis et al. 1960; O’Neal
et al. 1966). However, using tissue extraction, a few studies
have suggested a slow turnover rate of NAA in the rat brain
(Clarke et al. 1975; Kunnecke et al. 1993; Tyson and
Sutherland 1998). Interestingly a recent report by Moreno
et al. (2001) showed label incorporation from glucose into
NAA C2 only, although label incorporation into all three
resonances of NAA is expected, as demonstrated in our
preliminary work (Choi and Gruetter 2000).
In addition to NAA, another important molecule, GSH
can be measured in vivo in the brain using 13C NMR (Choi
et al. 2000). However, to date, the turnover of GSH has not
been demonstrated in the intact living brain in vivo,
possibly because of its slow metabolism. GSH, a sensitive
indicator of oxidative stress, plays a major role in the
protection against reactive oxygen species (Ketterer 1988;
Coyle and Puttfarcken 1993) and in the regulation of redox
status (Ogita et al. 1995; Varga et al. 1997). In addition to
its critical role as an antioxidant, GSH may serve as a
regulator of signal transduction for long-term potentiation
or apoptosis, may protect against the excitotoxic effects of
glutamatergic action (Coyle and Puttfarcken 1993), and
possibly is itself a neurotransmitter (Guo et al. 1992; Shaw
et al. 1996). Experimental evidence suggests a close
relationship between the decrease of GSH and neural
degeneration in animal (Benzi et al. 1988) and human
studies (Lang et al. 1992). GSH is not only related to
several neurodegenerative diseases but is also essential for
normal brain function (Bains and Shaw 1997; Dringen
et al. 1999).
The biosynthesis of GSH occurs from its precursors,
glycine and c-glutamylcysteine, through the action of the
enzyme, GSH synthetase. c-Glutamylcysteine is formed
from cysteine and glutamate by the enzyme, c-glutamyl
synthetase, which is normally the rate-limiting enzyme in
GSH synthesis (Chang et al. 1997). The biosynthesis of
GSH is also catalyzed by glutathione reductase, which uses
NADPH + H+ produced by the pentose phosphate pathway.
GSH has been measured using NMR in cells (Brown et al.
1977; Kuchel and Chapman 1983; Jans and Leibfritz 1988;
Skibsted and Hansen 1990; Dringen et al. 1998) and in
other organs (Farnsworth and Schleich 1985; Cohen 1987).
In the brain, an increase in GSH synthetase activity during
oxidative stress has been reported and GSH turnover was
determined in mice (Chang et al. 1997). Using in vivo 13C
NMR, cerebral GSH metabolism can be measured from the
label incorporation from 13C-labeled glucose into GSH
(Choi et al. 2000), and the turnover of GSH can be
determined non-invasively from a single animal. Following
infusion of [1-13C]glucose, the methylene group of
c-glutamylcysteine is labeled from the C4 methylene
carbon of glutamate (Glu C4), which is the label precursor
of the C4 methylene carbon of the glutamyl group of GSH
(GSH Glu C4).
In this study, we employed three-dimensionally localized
in vivo 13C NMR spectroscopy to detect 13C-label incorpor-
ation into NAA and GSH from 13C-labeled glucose. The aim
of the present study was (i) to measure in vivo metabolism,
turnover rates and compartmentation of NAA, a putative
neuronal marker, and (ii) to determine in vivo metabolism
and the turnover rate of GSH, an important antioxidant, in
the rat brain. A preliminary account of part of this work has
been published (Choi and Gruetter 2000).
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Materials and methods
Animal preparation
The study was performed according to the guidelines for the care
and use of laboratory animals at the University of Minnesota and
was approved by the Institutional Animal Care and Use Committee
(IACUC). Eight male Sprague-Dawley rats (265 ± 26 g,
mean ± SD) were fasted overnight (over 12 h) with free access to
water before studies. For preparation, animals were anesthetized
with 2% isoﬂurane (Marsam Pharmaceuticals, Cherry Hill, NJ,
USA) in a 1:1 mixture of nitrous oxide (N2O) and oxygen (O2),
intubated, and ventilated with a pressure-driven ventilator (Kent
Scientiﬁc, Litchﬁeld, CT, USA). Then catheters were inserted both
into femoral arteries and into veins. The arterial lines were used for
blood gas analyses and continuous monitoring of arterial blood
pressure. Arterial blood was sampled through a Teﬂon tubing line
(Spectrum Chromatography, Houston, TX, USA) for blood gas
analysis and glucose measurements at approximately 25-min
intervals. The venous lines were used for intravenous infusion of
a-chloralose and glucose. End-tidal CO2 was continuously monit-
ored with a capnometer (SC-300, BCI International, Waukesha, WI,
USA). A multitrace recorder (AcqKnowledge, Biopak Co., Santa
Barbara, CA, USA) was used for continuous recording of arterial
blood pressure and respiratory pressure pattern. Body temperature
was maintained at 37.0 ± 0.5C with a warm-water circulation
system based on feedback obtained from a rectal thermosensor (Cole
Palmer, Vernon Hills, IL, USA). After securing vascular access,
anesthesia was switched to a-chloralose with a bolus continuous
infusion [initial bolus of 40 mg/kg followed by a continuous i.v.
infusion of 24–26.7 mg/(kg h)], as described previously (Choi et al.
1999, 2001). The animals were secured using an in-house-built
Delrin holder with a bite bar and two ear inserts to provide a three-
point stereotaxic ﬁxation of the skull to minimize motion. The
animal was then placed in an acrylic holder attached to an insert
placed inside the gradient coil. A 20% weight/volume solution of
99%-enriched D-[1-13C]glucose (Isotec Inc., Miamisburg, OH, USA
and Cambridge Isotope Laboratories, Andover, MA, USA) was
infused into the left femoral vein according to the protocol used in
our previous studies (Choi et al. 1999, 2001, 2002, 2003). In brief,
the infusion rate of glucose was adjusted continuously throughout
the experiment based on the NMR signal of brain glucose and
concomitantly measured plasma glucose concentrations.
NMR methods
All experiments were performed on a 9.4 T, 31-cm horizontal-bore
magnet (Magnex Scientiﬁc, Abingdon, UK), interfaced to an
INOVA console (Varian, Palo Alto, CA, USA). An actively shielded
gradient coil with an 11-cm inner diameter (Magnex Scientiﬁc)
capable of switching to 300 mT/m in 500 ls was used. A quadrature
polarized 1H surface radiofrequency (RF) coil (14-mm diameter)
combined with a linearly polarized three-turn 13C RF coil (12-mm
diameter) was used as a transceiver for 1H NMR and 13C NMR
(Adriany and Gruetter 1997) and placed on the animal’s head (Choi
et al. 2001). A 99% 13C-enriched formic acid sphere placed at the
center of the 13C coil was used as an external reference (Choi et al.
1999). Automated localized shimming using a fully adiabatic
version of FASTMAP (Gruetter 1993) was used to adjust the
currents in all ﬁrst- and second-order shim coils, which were capable
of generating shim ﬁelds of up to 80 Hz/(cm2 A). The shim power
supply generated up to 4 A of current at maximal voltage of 24 V
(Resonance Research Incorporated, Billerica, MA, USA). Shimming
resulted in a full width at half-maximum of approximately 20 Hz of
the in vivo water signal in a nominal 500 lL volume
(8.5 · 6 · 10 mm3). Three-dimensional localization of the 13C
NMR signals based on outer volume suppression (Choi et al. 2000)
was applied to select a volume of interest (VOI). The VOI was
placed in the rat brain to avoid signal contamination from extra-
cerebral tissues such as adipose tissue and muscle, and the VOI
contained mostly cortical gray matter, given the sensitive proﬁle of
the RF coil and the small amount (8%) of white matter in the rat
brain (Choi et al. 1999, 2000, 2002). Data were acquired with a
repetition time (TR) of 1.5 s and an acquisition time of 150 ms.
During these times, bi-level WALTZ-16 decoupling was applied to
the proton channel for NOE (nuclear Overhauser effect) generation
between excitations and for decoupling during the acquisition time.
Spectral analysis was performed using the peak-ﬁtting algorithm
supplied by the spectrometer software. To reduce variability of peak-
ﬁtting, peak linewidths of 13C–13C doublets were set to that of the
corresponding center peak and the frequencies of the 13C–13C
doublets were set relative to the main resonance in spectra based on
their relative position determined in spectra summed for 1 h at
isotopic steady state. Concentrations of 13C label of NAA and GSH
were calculated from the area of the ﬁtted peaks, including the
doublets for NAA. The residual was visually inspected to verify
proper convergence of the peak ﬁtting routine.
The 13C-labeled NAA and GSH resonances were quantiﬁed using
the external reference method, as described previously (Choi et al.
1999). In short, in vivo 13C NMR signals were quantiﬁed by
comparison with the measurements of solutions containing 500 mM
NAA and 100 mM GSH. The external reference measurements were
performed under identical experimental conditions as in vivo. The
corrections of coil loading effect on sensitivity were assessed by
measuring the pulse duration of 180 for a square pulse applied
on-resonance to the signals of the 13C formic acid, which was placed
at the center of the 13C coil. The NOE and longitudinal relaxation
time (T1) effects were corrected by measuring the saturation factors
from the 13C signals with a TR of 7.5 s without NOE generation,
which is more than ﬁvefold longer than the T1 of metabolites (Choi
et al. 2000). The excitation proﬁle of the RF pulse, an adiabatic half-
passage pulse (pulse duration of 500 ls), led to 28% reduction of
the sensitivity at the chemical shift of NAA C2 region compared to
the on-resonance sensitivity, in addition to the increased chemical
shift displacement error at the NAA C2 region. The effect of limited
off-resonance excitation of the adiabatic RF pulse on quantiﬁcation
of 13C concentrations was inherently taken into account by the
external reference quantiﬁcation method.
NAA metabolism and modeling
The metabolic scheme of NAA metabolism is depicted in Fig. 1.
Following infusion of [1-13C]glucose, the C2 methyl carbon of
acetyl-CoA (acetyl-CoA C2) is rapidly labeled. This is the label
precursor of the C6 methyl carbon of the acetyl group of NAA
(NAA C6). The label in acetyl-CoA C2 enters the tricarboxylic acid
(TCA) cycle, where it is exchanged between the mitochondrial TCA
cycle intermediates and the large cytosolic amino acid pools, such as
glutamate C4 (Glu C4). The label continues through the TCA cycle
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and scrambles at succinate, a symmetric molecule. Successive label
incorporation into oxaloacetate results in the symmetric labeling of
the C2 methyne and C3 methylene carbons of aspartate (aspartate
C2 and C3) due to exchange with oxaloacetate, both of which are
the label precursors of the C2 methyne and C3 methylene carbons of
the aspartyl group of NAA (NAA C2 and C3). Therefore, as a result
of simultaneous synthesis and degradation of NAA, label incorpor-
ation into acetyl-CoA and aspartate from glucose is expected to
result in labeling of the NAA C6 and NAA C2, C3, respectively.
Metabolism of NAA C3 and C6 was modeled based on the
scheme in Fig. 1 using the following expressions (see Appendix for
derivation).
13NAA6ðtÞ
NAA
¼ 0:5 0:489eð
t
sNAAÞ ð1Þ
13NAA3ðtÞ
NAA
¼ 0:5 0:489ð1þ VNAA
NAA
sNAAsAsp
sNAA  sAspÞe
ð tsNAAÞ
þ 0:489VNAA
NAA
sNAAsAsp
sNAA  sAsp e
ð tsAspÞ
ð2Þ
The concentration and the metabolic rates of NAAwere assumed to
be in steady state with no net synthesis or degradation. It was further
assumed that the isotopic enrichment of acetyl-CoA, the precursor
of NAA C6, reaches steady state immediately compared to that of
NAA. The turnover rate of NAA C6 was calculated using eqn 1. The
isotopic enrichment of aspartate, the precursor of NAA C3, does not
reach steady state immediately; instead it is delayed by the label
exchange between intermediary metabolites in the mitochondrion
and the cytosolic amino acids. The turnover rate of NAA C3 was
calculated using a two-exponential ﬁt reﬂecting the delayed labeling
of aspartate expressed in an exponential input function (eqn 2). The
time constants for NAA (sNAA) and GSH (sGSH) turnover were
determined from the ﬁtting of the time courses of NAA and GSH.
The label half-life of NAA (T1/2 NAA) and that of GSH (T1/2 GSH)
were deﬁned as ln2ÆsNAA and ln2ÆsGSH, respectively.
In addition to the mathematical modeling (see above and
Appendix), isotopomer analysis of aspartate C3 and NAA C3 was
performed to characterize the pattern of label incorporation, which
provided additional information on the precursor–product relation-
ship between aspartate and NAA. The isotopomer analysis consisted
of signal integration of doublet and singlet signals of aspartate C3
and NAA C3 resonances, respectively. Singlet represents single
labeling of the C3 position of aspartate and NAA without respect-
ive labeling of the C2 position, whereas doublet represents double
labeling of aspartate and NAA in both C2 and C3 positions, where
the resonance is split by homonuclear 13C–13C J coupling. Thus, the
labeling ratio of doublet-to-(doublet + singlet) reﬂects the fraction
of simultaneous 13C labeling of C2 and C3 positions compared to
that of the C3 position.
Results
13C-label incorporation into the carbons of both the aspartyl
and acetyl groups of NAA was detected during [1-13C]glu-
cose infusion (Fig. 2a). The signal intensity of all three 13C
NMR resonances of NAA C3 (40.5 ppm), NAA C6
(22.8 ppm) and NAA C2 (54.0 ppm) clearly increased
progressively with time (Fig. 2a, 1024 scans each, TR ¼
1.5 s). It was interesting to note that the resonance of NAA
C6 (the acetyl moiety) appeared faster than that of NAA C2
and C3 (the aspartyl moieties), as shown in the time courses
(Fig. 3a). An expansion of the ﬁrst 4 h at higher temporal
resolution made the delay even more apparent (Fig. 3b).
Close inspection of the spectral region at 40.5 ppm contain-
ing the resonance of NAA C3 featured several additional
apparent resonances (Fig. 2b, top trace). Although the
GABA C4 resonance at 40.4 ppm was expected to contribute
to that spectral region, additional resonances were observed
that were attributed to the 13C–13C homonuclear coupling
within NAA C3 and GABA C4. This assessment was further
supported by peak ﬁtting that indicated a separation of 34 Hz
of these small resonances about their respective chemical
shift of both metabolites, consistent with the 13C–13C J
coupling constant typically seen for amino acids (Henry
et al. 2003). Therefore, the resonances around the NAA C3
at 40.5 ppm can be described as a combination of singly
labeled (singlet) and doubly labeled (doublet) NAA C3, and
singlet and doublet of GABA C4 signals (Fig. 2b, bottom
trace). The faster appearance of the resonances of GABA C4
compared to that of NAA C3 was consistent with the faster
GABA metabolism compared to that of NAA in the brain
in vivo.
The time course of NAA C6 was ﬁtted using eqn 1 and the
estimated turnover rate of NAA C6 was VNAA ¼
0.7 ± 0.1 lmol/(g h) with the time constant of NAA
C6 from the turnover ﬁt, sNAA6 ¼ 14 ± 2 h (mean ± SD,
Glc1
TCA
Cycle
NAA6
NAA2NAA3
Pyruvate
Acetyl-CoA2
Glu4
VNAA
VNAA VNAA
Acetate2
Asp3 Asp2
OAA3 OAA2 2-OG4
GSH Glu4
Fig. 1 Scheme of synthesis of N-acetyl aspartate (NAA) from glucose.
In this scheme, glucose labeled at the C1 position (Glc1) leads to
labeling of the C2 methyl carbon of acetyl-CoA (acetyl-CoA2) as a
result of glucose metabolism. The label then passes into the C6
position of NAA (NAA6) and the C2 and C3 positions of NAA (NAA2
and NAA3) after scrambling in the tricarboxylic acid (TCA) cycle, where
it exchanges label with the large amino acid pools such as glutamate
(Glu4). Labeling of aspartate C2 (Asp2) and C3 (Asp3) is influenced by
this exchange and is the precursor for labeling of the aspartyl moiety of
NAA. 2-OG, 2-oxoglutarate; OAA, oxaloacetate; GSH Glu4, the C4
methylene carbon of the glutamyl group of GSH.
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n ¼ 8). The time constant of aspartate C3 from the turnover
ﬁt (eqn A4), sAsp, was 1.0 ± 0.2 h (mean ± SD, n ¼ 8). For
NAA C3, the time course was ﬁtted using a two-exponential
ﬁt (Fig. 3) reﬂecting an exponential input function of
aspartate (eqn 2) and the estimated turnover rate of NAA
C3 was VNAA ¼ 0.6 ± 0.1 lmol/(g h) with the time constant
of NAA C3, sNAA3 ¼ 13 ± 2 h (mean ± SD, n ¼ 8). From
the ﬁts, the steady-state 13C concentrations of NAA C6 and
C3 were estimated at 4.2 ± 0.2 lmol/g and 3.8 ± 0.2 lmol/
g, respectively. The relationship between 13C isotopomers of
NAA C3 and aspartate C3 was analyzed using linear
regression of the doublet-to-(singlet + doublet) signal ratios
of NAA C3 and aspartate C3. Isotopomer analysis of NAA
C3 and aspartate C3 showed a linear relationship with a
slope of 0.81 ± 0.03 (slope ± ﬁt error, r ¼ 0.9, p ¼ 0.0015,
n ¼ 8, data not shown).
13C-label incorporation into the GSH Glu C4 at 32.2 ppm
was observed up to 19 h of [1-13C]glucose infusion (Fig. 4a).
Vertical stack plots of the averaged spectra with a temporal
resolution of 3 h (2048 scans each, TR ¼ 1.5 s) showed
substantially slower label incorporation of GSH Glu C4
compared to GABA C2 (35.12 ppm), glutamtate C4
1 Time (h)171395
NAA C3 
NAA C6 
NAA C2 
Asp C3
NAA C3
NAA C3
3738394041
4041
ppm
ppm
GABA C4
In Vivo
(a)
(b)
Fig. 2 Detection of progressive label incorporation into all three N-
acetyl aspartate (NAA) resonances. (a) Horizontal stack plots of NAA
C3 (40.5 ppm), NAA C6 (22.8 ppm) and NAA C2 (54.0 ppm) spectra
show label incorporation into NAA resonances up to 19 h of
[1-13C]glucose infusion (1024 scans each, TR ¼ 1.5 s). Resonance
intensities varied because of the radiofrequency excitation profile,
which was weaker at the C2 position. (b) The multiple resonances at
40.5 ppm were fitted and found to be consistent with a superposition of
multiplets (singlet + doublet) with 13C–13C homonuclear coupling of
34 Hz at the position of NAA C3 (40.5 ppm) as well as that of GABA
C4 (40.4 ppm). The brackets indicate the J coupling of 34 Hz. The
homonuclear 13C–13C coupling in the aspartyl moiety of NAA (NAA
C3) was found to be consistent with the isotopomer of aspartate C3
(upper trace). TR, repetition time.
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Fig. 3 Time-resolved observation of N-acetyl aspartate (NAA) meta-
bolism. (a) The detection of 13C-label incorporation into NAA C3 and
C6 during [1-13C]glucose infusion (see left axis). The time course of
aspartate C3 (triangles, see right axis) shows initial label delay
because of the flux rate of the TCA cycle and label exchanges
between intermediary metabolites. The label time constant of aspar-
tate C3, sAsp ¼ 1 h (dotted line), led to the delayed label incorporation
of NAA C3. (b) The initial time course of NAA shows time delay of label
incorporation of NAA C3 by 1.5 h compared to that of NAA C6,
consistent with the slower labeling of the precursor of NAA C3,
aspartate, compared to the precursor of NAA C6, acetyl-CoA, which
was assumed to mimic the labeling of plasma glucose (see Appendix).
Shown is the average data from eight animals.
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(34.27 ppm) and glutamine C4 (31.66 ppm). The estimated
turnover rate of GSH was 0.06 ± 0.02 lmol/(g h)
(mean ± SD, n ¼ 8) with the time constant of GSH from
the turnover ﬁt, sGSH ¼ 13 ± 2 h (mean ± SD, n ¼ 8).
Based on an exponential ﬁt (Fig. 4b), the steady-state 13C
concentration of GSH was estimated at 0.4 ± 0.1 lmol/g
(mean ± SD, n ¼ 8). Assuming that 50% of GSH was
labeled by 13C at inﬁnite time (because, at most, half of the
acetyl-CoA will be labeled from the [1-13C] glucose used),
the estimated total GSH concentration was 0.8 lmol/g,
which is comparable to the cortical GSH concentration in the
rat brain (Pfeuffer et al. 1999), suggesting complete turnover
of the GSH pool in the brain in vivo.
Discussion
This study reports the measurement of label incorporation
into the acetyl as well as the aspartyl moieties of NAA in
three resonances of NAA, i.e. the NAA C2, C3 and C6
(Fig. 2a) in the intact rat brain in vivo. In addition, 13C–13C
homonuclear coupling of NAA C3 and GABA C4 was
discovered. It was interesting to note that approximately 2 h
after starting the infusion of [1-13C]glucose, the acetyl (C6)
as well as the aspartyl (C2 and C3) signals of NAA clearly
increased with time (Fig. 2a). An early study in brain extracts
observed labeling of the acetyl moiety of NAA but not that of
the aspartyl moiety 2 h after administering label (Kunnecke
et al. 1993). Their observation is consistent with our study,
which showed that label incorporation into the aspartyl
moiety was delayed by approximately 1.5–2 h. The question
thus arises as to how the amount of label incorporated into
the two NAA moieties could differ and be delayed. The data
presented in this study suggests that the delayed label
incorporation into NAA C3 is a result of the delayed labeling
of the precursor of NAA C3, namely aspartate C3, compared
to the labeling of the precursor of NAA C6, namely acetyl-
CoA C2. As illustrated in Fig. 1, label from glucose labeled
in the C1 position will be incorporated into the C2 position of
acetyl-CoA, which leads to labeling of NAA C6. It is
assumed that the labeling of acetyl-CoA C2 is much faster
than that of aspartate C3, because acetyl-CoA is the label
precursor of aspartate through the TCA cycle. In addition, in
order for label to be incorporated into the aspartyl moiety of
NAA (NAA C3), aspartate needs to be labeled ﬁrst, which
happens through transamination of oxaloacetate, a TCA
cycle intermediate. As the label enters the TCA cycle from
acetyl-CoA, it ﬁrst labels the C4 of 2-oxoglutarate, which
exchanges label with glutamate, whose concentration is
approximately 10 lmol/g in the mammalian brain. Recent
studies have indicated that this exchange rate is on the order
of the rate of the pyruvate dehydrogenase ﬂux (Gruetter et al.
2001; Choi et al. 2002; Henry et al. 2002), and the size of
the glutamate pool can signiﬁcantly affect the labeling of the
TCA cycle intermediates (Gruetter et al. 2001). Thus, the
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Fig. 4 Time-resolved observation of glutathione (GSH) metabolism
in vivo. (a) Time course of 13C-label incorporation into GSH Glu C4
(32.2 ppm, vertical dotted line) up to 19 h of [1-13C]glucose infusion.
GSH appears very slowly compared to GABA C2 (35.1 ppm), glu-
tamate C4 (Glu C4, 34.27 ppm) and glutamine C4 (Gln C4, 31.7 ppm),
which reach steady state much more rapidly. Each spectrum in the
stack plot is averaged with a temporal resolution of 3 h (2048 scans
each, TR ¼ 1.5 s) and mean values of each time interval are shown in
the right axis. The resonance of glutamate C4 at 34.27 ppm was used
as a reference for all peak assignments of the spectra. Note that the
GSH resonance continues to increase over time, whereas the GABA
C2 and Glu C4 resonances are close to constant in time, indicating
much faster turnover, consistent with our previous results (Pfeuffer
et al. 1999). TR, repetition time. (b) The time course of GSH shows a
very slow turnover rate of VGSH  0.06 lmol/(g h) and time constant
of sGSH ¼ 13 h. Shown is the average of eight animals.
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label incorporation into the aspartyl moiety of NAA from
glucose that involves label scrambling in the TCA cycle and
label exchange with amino acid pools (Fig. 1) delays
the labeling of aspartate by 1.5 h (Fig. 3a), whereas
13C-labeled glucose reaches steady state very rapidly (Choi
et al. 2002). Because the label precursor of the aspartyl
moiety of NAA was labeled more slowly than the label
precursor of the acetyl moiety of NAA, the labeling of NAA
C3 was delayed compared to that of NAA C6, as observed in
this study (Fig. 3).
The simultaneous observation of label incorporation into
both acetyl and aspartyl groups of NAA can provide insights
into metabolic compartmentation and biosynthesis of NAA.
First, the current data can be interpreted as NAA synthesis in
a single metabolic compartment, as described above. This
was further supported by the isotopomer analysis. Second, as
the synthesis of NAA has been ascribed to the neuronal
mitochondria (Benuck and D’Adamo 1968; Clark 1998), the
current data is consistent with the labeling of aspartate
representing mainly the neuronal compartment (Gundersen
et al. 2001). The observation of similar labeling patterns and
isotopic enrichment between NAA and aspartate suggests
that aspartate is the precursor of NAA and supports the
hypothesis that NAA synthesis occurs in the neuronal
compartment.
From ﬁtting a mathematical model of NAA metabolism
(see Fig. 1 and Appendix), the steady-state concentration of
13C label was calculated in both the aspartyl and acetyl
moieties of NAA. The steady-state 13C pool size of NAA
was 4 lmol/g, which indicated complete turnover of
NAA when considering that the total concentration of NAA
in these regions of the rat brain is approximately 8–9 lmol/
g (Pfeuffer et al. 1999; Choi and Gruetter 2003) and
that 13C label represents maximum 50% of the total
concentration of NAA. Complete turnover of NAA requires
2–3 days in the rat brain, as judged from the label time
constant of NAA, sNAA ¼ 13–14 h. Therefore, we con-
clude that NAA was synthesized very slowly [0.6–
0.7 lmol/(g h)] from its precursors, neuronal acetyl-CoA
and aspartate, and accounts only for a very small fraction
of overall brain glucose metabolism under resting normoxic
conditions. In addition, preliminary evidence suggested that
NAA concentrations were not affected by extended periods
of hypoglycemia (data not shown), further supporting the
notion that NAA does not serve as an energy-buffering
store in the rat brain.
The turnover rate of GSH was found to be equivalent to
that of NAA in the rat brain in vivo, but much slower
compared to that of other amino acids such as glutamate,
glutamine and GABA. Rapid turnover of the GABA pool
was indicated, as expected by the early appearance of the C4
and C2 methylene groups of GABA in Fig. 2(a) (top trace)
and Fig. 4(a), respectively. The steady-state 13C concentra-
tion of GSH was 0.4 lmol/g, which is half of the GSH
content in the rat brain in vivo measured by 1H NMR
spectroscopy (Pfeuffer et al. 1999; Tkac et al. 2003), as
expected for complete turnover from glucose. The GSH
turnover in the living intact brain in vivo may provide an
important parameter in monitoring metabolic alterations of
GSH during oxidative stress in aging and neurodegenerative
diseases.
Conclusions
In conclusion, labeling from glucose suggests complete
turnover of NAA, with the synthesis occurring in a single
kinetic compartment. Furthermore, we conclude that NAA is
not likely to serve as a signiﬁcant buffer of acetyl-CoA units
for brain energy metabolism at rest. To what extent NAA
may provide acetyl-CoA units under conditions of substrate
deprivation remains to be determined. It is thus more likely
that NAA plays a role in biosynthetic processes that remain
to be identiﬁed.
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Appendix
Mathematical model of N-acetyl aspartate metabolism
The scheme in Fig. 1 was used to model the rate of 13C-label
incorporation into NAA C3 and C6. In this metabolic model,
steady state was assumed, i.e. the concentration and the
metabolic rates of NAAwere assumed to be constant in time.
It was further assumed that the isotopic enrichment of acetyl-
CoA was raised to a steady-state value very rapidly
compared to the rate of NAA turnover. This assumption
was justiﬁed by the rapid rise in the isotopic enrichment of
plasma glucose.
Using mathematical formulations intrinsic to tracer (or
labeling) studies (Mason et al. 1992; Gruetter et al. 1998a),
the metabolic modeling of the rate of 13C-label incorporation
into NAA C6, 13NAA6, can be expressed as a differential
equation,
d13NAA6
dt
¼ VðinÞNAA
13Acetyl-CoA2
Acetyl-CoA
 VðoutÞNAA
13NAA6ðtÞ
NAA
ðA1Þ
where 13Acetyl-CoA2/Acetyl-CoA is the isotopic enrichment
of acetyl-CoA (assumed to be 0.5 times that of glucose) and
NAA is the total concentration of NAA. V ðinÞNAA is the
synthesis rate of NAA and V ðoutÞNAA is the degradation rate of
NAA. At steady state no net synthesis of NAA occurs by
deﬁnition, hence V ðinÞNAA ¼ V ðoutÞNAA ¼ VNAA.
With negligible concentration changes of NAA as evi-
denced by 1H NMR spectroscopy, synthesis and degradation
rates of NAA are the same and equal to VNAA. The solution
of eqn A1 is
13NAA6ðtÞ
NAA
¼ Aþ Beð
t
sNAAÞ ðA2Þ
where sNAA ¼ NAA/VNAA, and A and B are the con-
stants determined by the initial and ﬁnal conditions,
i.e. 13NAA6(t ¼ 0) ¼ 0.011 NAA and 13NAA6(t ¼ ¥) ¼
0.5 NAA, which are 1.1% natural abundance of 13C label
before infusion of 13C-enriched glucose (t ¼ 0) and 50% of
13C label at inﬁnite time (t ¼ ¥), respectively, which leads to
eqn 1.
Unlike the labeling of acetyl-CoA, that of aspartate does
not reach steady state immediately, instead it is delayed
because of label exchange between intermediary metabolites
in the mitochondrion and the cytosolic amino acids. The
calculation that follows demonstrates that delayed labeling of
aspartate C2 and C3 results in further delayed labeling of
NAA C2 and C3 that can be explicitly expressed in
mathematical terms. The metabolic modeling of the rate of
label incorporation into NAA C3 (the same for NAA C2) can
be expressed as
d13NAA3
dt
¼ VNAA
13Asp3ðtÞ
Asp
 VNAA
13NAA3ðtÞ
NAA
ðA3Þ
where 13Asp3 is the
13C concentration of aspartate C3 and
Asp is the total concentration of aspartate.
The rate of 13C-label incorporation into the C3 of aspartate
can be modeled in a similar manner as 13NAA6 in eqn A2 as
13Asp3ðtÞ
Asp
¼ Cþ Deð
t
sAspÞ ðA4Þ
where in our experiments, C ¼ 0.5 and D ¼ ) 0.489.
A trial solution for eqn A3 can be expressed as
13NAA3ðtÞ
NAA
¼ Eþ Feð
t
sNAAÞ þ Geð
t
sAspÞ ðA5Þ
Taking the derivative of eqn A5 and equating it with eqn A3
yields the following relationships:
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sNAA ¼ NAA=VNAA; ðA6Þ
E ¼ C ¼ 0:5; ðA7Þ
G ¼ D sAsp
sNAA  sAsp ¼ 0:489
sAsp
sNAA  sAsp ðA8Þ
Constant F is determined by the initial condition of 13NAA3
(t ¼ 0) ¼ 0.011 NAA and eqns A7 and A8, which leads to
eqn 2.
A slower initial rate of label incorporation into NAA C3
compared to that into NAA C6 can be explained by the
presence of the last term in eqn 2, which has a positive
coefﬁcient because sNAA > sAsp. If the aspartate pool turns
over very fast (sAsp  0), eqn 2 will be equivalent to eqn 1
with no time lag in the labeling of NAA C3.
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